U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula CO3.Ca.Cl.2K.Mg.3HO
Molecular Weight 289.064
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 2

SHOW SMILES / InChI
Structure of CALCIUM MAGNESIUM POTASSIUM CARBONATE CHLORIDE HYDROXIDE

SMILES

[OH-].[OH-].[OH-].[Mg++].[Cl-].[K++].[K++].[Ca++].[O-]C([O-])=O

InChI

InChIKey=RUGQTQJQCSDUFS-UHFFFAOYSA-H
InChI=1S/CH2O3.Ca.ClH.2K.Mg.3H2O/c2-1(3)4;;;;;;;;/h(H2,2,3,4);;1H;;;;3*1H2/q;+2;;3*+2;;;/p-6

HIDE SMILES / InChI
VASCULERA (diosmiplex) consists of diosmin glycoside in combination with alkaline granules, alka4-complex. Alka4-complex contains 30 mg of a proprietary, structured, highly alkaline agglomeration of reactive magnesium hydroxide (Mg(OH)2, molecular weight 58.3), potassium chloride (KCl, molecular weight 74.6) and potassium hydroxide (KOH, molecular weight 56.1) held apart from each other in a matrix of calcium carbonate (CaCO3, molecular weight 100.1), microcrystalline cellulose and croscarmellose sodium. VASCULERA is indicated for the clinical dietary management of the metabolic processes associated with chronic venous insufficiency (CVI). VASCULERA acts by restoring toward normal the metabolic aspects of CVI including modulation of venous tone and capillary resistance, management of lymphatic drainage, and inflammation in the microcirculation. Alka4-complex has been shown in preclinical and clinical studies to act as an acid buffering agent in the gut and to counteract the effects of increased acid production systemically. Clinical studies have shown that alka4-complex in VASCULERA can reduce acidosis under extreme exercise loads. The specially agglomerated matrix of alka4-complex has been shown to resist neutralization by acid solutions. In addition, the alka4-complex has been shown to reduce the acid producing effects of certain foods by buffering the acidity in the gastrointestinal tract, while allowing a sufficient portion of the complex to survive in the stomach, and is absorbed in the small intestine thereby being available to manage mild acidosis.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
VASCULERA

Approved Use

Unknown

Sample Use Guides

VASCULERA can be taken with or without food.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
CALCIUM MAGNESIUM POTASSIUM CARBONATE CHLORIDE HYDROXIDE
WHO-DD  
Systematic Name English
ALKA4-COMPLEX
Common Name English
Alka 4-complex [WHO-DD]
Common Name English
Code System Code Type Description
DAILYMED
Z7R65IFU98
Created by admin on Fri Dec 15 15:48:50 UTC 2023 , Edited by admin on Fri Dec 15 15:48:50 UTC 2023
PRIMARY
DRUG BANK
DB14497
Created by admin on Fri Dec 15 15:48:50 UTC 2023 , Edited by admin on Fri Dec 15 15:48:50 UTC 2023
PRIMARY
SMS_ID
300000036098
Created by admin on Fri Dec 15 15:48:50 UTC 2023 , Edited by admin on Fri Dec 15 15:48:50 UTC 2023
PRIMARY
FDA UNII
Z7R65IFU98
Created by admin on Fri Dec 15 15:48:50 UTC 2023 , Edited by admin on Fri Dec 15 15:48:50 UTC 2023
PRIMARY
CAS
1224727-39-2
Created by admin on Fri Dec 15 15:48:50 UTC 2023 , Edited by admin on Fri Dec 15 15:48:50 UTC 2023
PRIMARY